With the aim of coordinating cardiovascular research in Göttingen, the Heart Research Center Göttingen (HRCG) was founded in 2010. Within the center, all research projects are coordinated. The members comprise the Heart Center Göttingen at the University Medical Center Göttingen, institutes of the Georg August University Göttingen, the three Max Planck Institutes (Max Planck Institute for Biophysical Chemistry, Max Planck Institute for Dynamics and Self Organization, Max Planck Institute for Experimental Medicine) as well as the German Primate Center.

Furthermore, at the Collaborative Research Center 1002, “Modulatory Units in Heart Failure”, funded by the German Research Foundation (DFG), the foundations are laid for the development of new therapeutic strategies for heart failure. The goal of the German Center for Cardiovascular Research (DZHK) is to rapidly translate research findings into new treatment approaches for patients with heart disease.

Göttingen is one of seven partner universities of the DZHK that were selected by an international review board based on their academic excellence.

Göttingen also coordinates large projects funded by the European Commission to research cardiac arrhythmias, providing a base for a variety of highly qualified research projects. To house these diverse research projects, a new research facility was built in 2017.

In 2018, construction will begin on the new Heart and Brain Center Göttingen (HBCG). Experts in heart and brain research are already working together to gain new insights into diseases of both organs, and discover novel treatment strategies. The new infrastructure will also further strengthen the cooperation with neurological research groups.

Research projects are financed by various research promotion bodies. In each case, funding is preceded by in-depth assessments.

Funding through the European Union
The project EUTrigTreat is being funded since 2009 by the EU's Seventh Framework Programme (FP7). EUTrigTreat includes twelve academic institutions and three medium-sized enterprises from a total of nine European countries and the USA. The project investigates molecular mechanisms of potentially life-threatening cardiac arrhythmias and develops new therapeutic strategies of pharmacologic and technical nature. Coordinator is Prof. Dr. S. E. Lehnart. 

Funding through the Federal Ministry of Education and Research (BMBF)
The Göttingen location (Heart Research Center Göttingen, HRCG) is member of the German Center of Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung, DZHK).

Funding is managed through the National Genome Research Network (Nationales Genomforschungsnetz). The Göttingen location has been a member of this network since 2001.

Funding through the German Research Foundation (DFG)
Collaborative Research Center 1002 (SFB 2001): Modulatory Units in Heart Failure (Modulatorische Einheiten bei Herzinsuffizienz). The CRC is devoted to identify new treatment strategies for heart failure at a microdomain level.
Furthermore there are projects of individual support from the German Research Foundation (DFG) as well as support from the Federal Ministry of Education and Research (BMBF).

International research promotion by the Fondation Leducq (Transatlantic Networks of Excellence)
Since 2009: “Redox and Nitrosative Regulation of Cardiac Remodeling: Novel Therapeutic Approaches for Heart Failure”
Since 2008: “Alliance for Calmodulin Kinase II Signaling in Heart Failure and Arrhythmias”



Press Release DZHK (German) 

Press Release CRC 1002 (English)